Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zealand Pharma says data presented by Sanofi support flexibility in timing of administration for Lyxumia


Thursday, 5 Dec 2013 01:17am EST 

Zealand Pharma A/S:Says Sanofi has provided results of a 24-week Phase IIIb clinical study showing that Lyxumia (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast or before the main meal of the day.Says these results support that lixisenatide can effectively lower blood sugar at either time of administration.Says the results also showed that a mean change in body weight of -2.6 to -2.8kg, was achieved regardless of the meal before which lixisenatide was administered.Says in the study gastro-intestinal tolerability was comparable regardless of time of administration, with no cases of severe hypoglycemia.Says Lyxumia was invented by Zealand for the treatment of Type 2 diabetes and is licensed globally to Sanofi. 

Company Quote

67.5
0.5 +0.75%
11 Jul 2014